ArriVent BioPharma, Inc. AVBP Ratios & Valuation
| FY'25 | FY'24 | ||
|---|---|---|---|
| Returns | |||
| Return on equity | -58.9%— | —— | |
| Return on assets | -54.7%-17.9pp | -36.7%— | |
| Return on invested capital | -79.7%— | —— | |
| Liquidity | |||
| Current ratio | 12.8×-0.3× | 13.1×-0.6× | |
| Quick ratio | 12.8×-0.3× | 13.1×-0.6× | |
| Cash ratio | 1.8×-2.5× | 4.3×-8.6× | |
| Leverage | |||
| Debt-to-equity | 0×0.0× | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | |
| Per Share | |||
| Book value per share | $7.99-2.4% | $8.19+111% | |
| Valuation | |||
| Market capitalization | $830.58M-7.5% | $897.69M— | |
| Enterprise value | $785.05M-4.7% | $823.58M— | |
| Price / book | 2.7×-0.8× | 3.5×— | |
| Earnings yield | -20%-11.1pp | -9%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do ArriVent BioPharma, Inc.'s ratios come from?
- Every ratio is computed from ArriVent BioPharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.